A Conversation with Emil Jacobs
and J. Craig Venter
October 26, 2011
5:30 p.m. to 8:30 p.m.
BioScience Research Collaborative
6500 Main Street, between University Blvd and Dryden Rd
||Open to the Public
Online registration is now closed.
Emil Jacobs of ExxonMobil and J. Craig Venter of Synthetic Genomics will discuss their alliance to research and develop biofuels from photosynthetic algae with CHF’s Thomas R. Tritton.
This event is the final session of the 2011 Chao Symposium. Online registration for this event is now closed. For further information, contact Laura Naden, CHF’s advancement and events administrator, at 215.873.8276 or email@example.com.
5:30 p.m. Cocktail reception
6:30 p.m. History Live Conversation
7:30 p.m. Dessert and coffee
The Bioscience Research Collaborative is located at 6500 Main Street, between University Boulevard and Dryden Road (across the street from the far southeast corner of the campus). Visitor Parking is available in the underground parking garage on Dryden Road. Guests will self-pay for parking in the garage. The parking rate for 2 hours is $11 and up. Cash and credit are accepted.
About the speakers
Emil Jacobs is vice president of research and development of the ExxonMobil Research and Engineering Company, a position he has held since 2002. Jacobs joined the firm in 1978 as a research engineer. In 1999 he was named global vice president of basic chemicals and intermediate technology, and he was heavily involved in the Exxon/Mobil merger transition team.
Jacobs is a member of the Chemical Engineering Advisory Council at Princeton University, the Advisory Board of the College of Chemistry at the University of California, Berkeley, the Industrial Research Institute, and the Research and Development Council of New Jersey. He is also a member of the American Chemical Society and the American Institute of Chemical Engineering. Jacobs has a B.S. in chemical engineering from Rice University and a Ph.D. in chemical engineering from Princeton University.
J. Craig Venter
J. Craig Venter is founder, chairman, and president of the J. Craig Venter Institute (JCVI), a not-for-profit research organization dedicated to human, microbial, plant, synthetic and environmental genomic research and the exploration of social and ethical issues in genomics. Venter is also founder and CEO of Synthetic Genomics Inc.
After earning both a bachelor’s degree in biochemistry and a Ph.D. in physiology and pharmacology from the University of California, San Diego, Venter was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984 he moved to the National Institutes of Health, where he developed expressed sequence tags or ESTs, a revolutionary strategy for rapid gene discovery. In 1992 Venter founded The Institute for Genomic Research, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae. In 1998 he founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal Science.